ASPIRIN has been shown to cause gastrointestinal bleeding. Although the blood loss associated with the relatively small dosage that is customarily used is slight (usually well below 10 ml. per day),' there are some situations in which the safety of aspirin may be questioned. Such a situation is the administration of aspirin to patients who are simultaneously receiving anticoagulant therapy. Some authors have, in fact, recommended that such patients should not use salicylates in any form.2 3 In view of the increasing number of patients who are receiving anticoagulants on a long-term basis, and the ubiquitous use of aspirin, it is important to know whether significant increase in gastrointestinal blood loss occurs in the presence of this combination of agents. The present study was designed to evaluate the safety of salicylate ingestion in combination with anticoagulation, under controlled conditions. In addition, the possible effect of salicylate ingestion on the dosage of anticoagulant needed to produce satisfactory levels of hypoprothrombinemia was studied. Method The group under study consisted of sixteen men and nine women who were patients on the medical wards of St. Luke's Hospital. These patients, whose ages ranged from 31 to 85, were receiving acenocoumarin* to prevent complications of coronary artery disease, thrombophlebitis, and atrial fibrillation.
Erythrocytes were labeled with sodium radiochromate and reinjected according to a previously described method, and fecal blood content was calculated from the ratio of fecal:blood radioactivity. In order to determine the effect of aspirin upon prothrombin activity, the average daily maintenance dosage of acenocoumarin was calculated both before and during the week in which aspirin was given.
Results

Fecal Blood Content
Results were obtained for fecal blood loss in 20 patients for control periods, and for 188 patients for aspirin periods. Seventeen patients completed both aspirin and control periods. The observations are summarized in figure 1 , in which two groups of subjects are compared: the group receiving anticoagulants during both aspirin and control periods, and a group of 131 normal volunteers who were similarly evaluated during both aspirin and control periods. The average daily blood loss in the anticoagulant group was 1.1 ± Daily fecal blood loss.
1.5 ml., or 21/2 standard deviations above their own mean control level during aspirin period. Of the subjects receiving the anticoagulant, 76 per cent showed a daily blood loss in excess of 1.5 ml. during the aspirin periods. Since the control level of the latter group is higher, however, the establishment of an acceptable "significant" increase in rate of bleeding is correspondingly higher. Thus, 67 per cent of the subjects receiving anticoagulants had a daily blood loss during the aspirin period that was 21/2 standard deviations, or more, above their own control level.
Alterations in Anticoagulant Dosage
Seventeen patients were observed for a sufficient length of time both with and without aspirin to calculate average daily maintenance dosages of acenocoumarin ( fig. 2) . Eleven of these patients required a reduction in daily acenocoumarin dosage of 0.5 mg. or more. These patients were maintained on a daily average of 3.1 mg. of acenocoumarin during the control period and 2.2 mg. during the aspirin period. Five other patients required a dosage reduction of less than 0.5 mg.; this was not considered significant because of the inaccuracy of dividing the 4-mg. tablet. Only one patient had an increase in maintenance dosage while taking aspirin, and this increment was only 0.5 mg. The daily blood loss in those patients in whom aspirin seemed to have a hypoprothrombinemic effect was no greater than in the others. Thus, there was no correlation between bleeding tendency and aspirin-induced hypoprothrombinemia.
Complications
Anticoagulant therapy had to be discontinued in four patients during the course of the study. One of the patients experienced frequent episodes of epistaxis while taking aspirin, but he had previously shown an elevation in fecal blood content (7.2 ml. per day) during the control period. Another patient had a sudden episode of rectal bleeding during which 140 ml. of blood were lost; the source of this bleeding was believed to be hemorrhoidal. A third patient developed gross hematuria before aspirin was started. The fourth had an episode of upper gastrointestinal bleeding, also before aspirin was started. Thus, aspirin could not be incriminated in any of these complications. These patients are not included in table 1 14 and a lowered prothrombin activity.'1 In the present study, and in a previous study of normal volunteers,19 lowered prothrombin activity was not correlated with daily blood loss. The results suggest, however, that an already low prothrombin level might, in an occasional patient, be further depressed to a dangerous level. Such an incident was not observed in this group of patients because prothrombin determinations were performed every day, and appropriate dose adjustments were made. Since the rate of bleeding did not appear to be influenced by anticoagulation, it would be tempting to deny any hazard in the use of aspirin. More extensive bleeding has been observed, however, in 5 to 10 per cent of normal volunteers studied in this laboratory (up to 85 ml. per day). Since no such persons were found in this study group, it is impossible to predict the influence of anticoagulation upon "susceptible" persons with aspirininduced bleeding of this magnitude.
Summary and Conclusions A group of patients receiving oral anticoagulants was studied during control periods and periods during which aspirin was administered, with respect to rate of blood loss via the gastrointestinal tract. These patients did not bleed at a significantly greater rate than did previously studied normal volunteers, when taking aspirin; however, the anticoagulant group showed a slightly higher blood loss during the control period.
The majority of patients showed a slight though detectable decrease in prothrombin activity, as evidenced by a reduction in anticoagulant dosage, during the aspirin period. The results of this study indicate that aspirin, in a dose of 600 mg. four times daily. rendered no apparent increased hazard of gastrointestinal bleeding in the small group of subjects without evident gastrointestinal disease studied. Patients who must take aspirin continuously, however, may require a reduction in anticoagulant maintenance dosage.
